Which is the role of post-dilation after DES implantation? Enrico Romagnoli 1,2 M.D., Ph.D. 1 Policlinico Casilino, Roma 2 Opedale San Raffaele, Milano.

Slides:



Advertisements
Similar presentations
Clinical Trial Results. org ABSORB Presented at the American College of Cardiology Annual Scientific Session March, 2007 Presented by Dr. Patrick W. Serruys.
Advertisements

“Real World”: SVG, De Novo or Restenotic Coronary Artery Lesions Chronic Stable Angina, Silent Ischemia, Acute Coronary Syndromes Vessel Diameters:
TAVOLA ROTONDA Quale Ruolo Clinico e Quale Rimborso per la Franctional Flow Reserve? Correlazioni anatomo-funzionali FFR vs IVUS Luigi Vignali, Parma Bologna.
PCI Unmet Clinical Needs
STENT THROMBOSIS: WHICH IMPACT IN REAL CLINICAL PRACTICE? Giuseppe Biondi Zoccai Divisione di Cardiologia, Università di Torino Ospedale S. Giovanni Battista.
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
Calcified vessels – balloons that cut Azfar Zaman Freeman Hospital, Newcastle-upon-Tyne.
Www. Clinical trial results.org The RAVEL Study A RAndomised (double blind) study with the Sirolimus coated BX™ VElocity balloon expandable stent (CYPHER™)
Can we prevent stent restenosis after coronary stent implantation
Francesco Burzotta HOTLINE III, ESC Congress 2007 September 4th 2007, Vienna OPTIMIST: the Outcome of Pci for stent-ThrombosIs MultIcentre STudy Institute.
Optimal Stent Expansion and Optimization
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Published in Circulation 2005 Percutaneous Coronary Intervention Versus Conservative Therapy in Nonacute Coronary Artery Disease: A Meta-Analysis Demosthenes.
C. Graidis, D. Dimitriadis, A. Ntatsios, V. Karasavvides
Govt. Medical College, Calicut
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Tips and Pitfalls in Measurement of FFR during Bifurcation Stenting Nanjing first hospital Nanjing cardiovascular hospital Yefei Chenshaoliang Zhangjunjie.
Technical approach PCI in Small Vessels Washington Cardiology Center Augusto Pichard, L. Satler, K. Kent, R. Waksman, J. Laird, W. Suddath, J. Sharretts,
1 SIROLIMUS-ELUTING STENTS FOR IN-STENT RESTENOSIS TREATMENT IN 278 UNSELECTED PATIENTS: INSIGHTS ON LONG-TERM OUTCOMES FROM A LARGE TWO-CENTER REGISTRY.
Arterial Revascularization Therapies Part II: a non- randomized comparison of contemporary PCI and coronary artery bypass grafting (CABG) in patients with.
The REALITY Study Results. REALITY Study Design The REALITY Study : Prospective randomized clinical trial to evaluate the safety and efficacy of CYPHER®
Treatment of In-Stent Restenosis by Paclitaxel Coated PTCA Balloons Presented at The American Heart Association Scientific Session 2006 Presented by Dr.
SIROLIMUS-ELUTING STENTS EFFECTIVELY INHIBIT NEOINTIMAL PROLIFERATION AS COMPARED TO BARE METAL STENTS IN DISEASED SAPHENOUS VEIN GRAFTS: 6-month IVUS.
Intravascular ultrasound does not provide any significant clinical benefit for percutaneous coronary intervention of bifurcation lesions Giuseppe Biondi.
LM strategy Interventional cardiology dpt Cardiovascular Hospital - Lyon - France Gilles Rioufol MD PhD INSERM U1060 High Tech Marseille, 26 Janvier 2012.
TCT 2012 Revascularization Strategies for Complex Left Main Disease and Left Coronary Ostial Disease Alfredo E. Rodriguez, MD, PhD, FACC, FSCAI Centro.
左主干分叉病变治疗策略的选择 Left main bifurcation: what is the best choice? Lei Ge, MD Department of Cardiology, Zhongshan Hospital, Fudan University.
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
Cardiac catheterization Labs
LONG-TERM CLINICAL OUTCOMES AFTER REPEAT DRUG-ELUTING STENT IMPLANTATION FOR IN DRUG-ELUTING STENT RESTENOSIS. C. Graidis, D. Dimitriadis, A. Ntatsios,
Direct Stenting is Better (Debate Session) 동아의대 김 무 현.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
Saqib Chowdhary Wythenshawe Hospital STENT THROMBOSIS How Do IVUS & OCT Help.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Date of download: 6/2/2016 Copyright © The American College of Cardiology. All rights reserved. From: Retrograde Techniques and the Impact of Operator.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
R4 하 상 진. Introduction Circulation May 1;115(17):
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Pulmonary Vein Stenosis Complicating Ablation for.
The GREAT Trial. The Grampian Region Early Anistreplase Trial Reference Zahringer M, Sapoval M, Pattynama PM, et al. Sirolimus-eluting versus bare-metal.
Date of download: 6/25/2016 Copyright © The American College of Cardiology. All rights reserved. From: Implantation of a Drug-Eluting Stent With a Different.
Influence of a Pressure Gradient Distal to Implanted Bare-Metal Stent on In-Stent Restenosis After Percutaneous Coronary Intervention Lisette Okkels Jensen,
Results From the MISSION! Intervention Study Sirolimus-Eluting Stents Vs Bare-Metal Stents in Patients With STEMI : 9-Month Angiographic and Intravascular.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Severe Neointimal Hyperplasia of Neoplastic Carina.
Date of download: 7/9/2016 Copyright © The American College of Cardiology. All rights reserved. From: Kissing Balloon or Sequential Dilation of the Side.
Date of download: 7/10/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Coronary Anatomy and Stenting Technique.
Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Efficacy and Safety of Dual Antiplatelet Therapy.
Intravascular ultrasound (IVUS) in percutaneous coronary intervention – summary of key articles While angiography is routinely used for assessment of CAD,
Intravascular ultrasound (IVUS) in the treatment of long and diffuse lesions– summary of key articles Prepared by Radcliffe Cardiology 21 November2016.
Disclosure Statement of Financial Interest
Latvian Centre of Cardiology real-life registry
Clinical Usefulness of Post-Stenting FFR
(DES)+BVS +DCB for long diffuse LAD disease
LONG-DES II Trial Randomized Comparison of the Efficacy of Sirolimus-Eluting Stent Versus Paclitaxel-Eluting Stent in the Treatment of Long Native Coronary.
Debate: What Does the Future Hold for the Treatment of Unprotected Left Main Disease? More PCI No More Routine Surgery Ron Waksman, MD, FACC Washington.
OCT-Guided PCI What needs to be done to establish criteria?
The Hidden Cost of Underutilizing PCI for Chronic Total Occlusions
Stenting of Coronary Arteries in Non Stress/Benestent Disease
Circ Cardiovasc Interv
Catheter-Based Treatment of Coronary Artery Disease
Early strut coverage in patients receiving new-generation drug-eluting stents and its implications for dual antiplatelet therapy: a randomized clinical.
Impact of calcium on procedural and clinical outcomes in lesions treated with bioresorbable vascular scaffolds - A prospective BRS registry study  Jiang.
Giuseppe Biondi Zoccai, MD
The American College of Cardiology Presented by Dr. Raimund Erbel
Bifurcation Disease: Simulation Training Curriculum
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
12-month clinical and 13-month angiographic outcomes from a randomized trial evaluating the Absorb Bioresorbable Vascular Scaffold vs. metallic drug-eluting.
Maintenance of Long-Term Clinical Benefit with
Presentation transcript:

Which is the role of post-dilation after DES implantation? Enrico Romagnoli 1,2 M.D., Ph.D. 1 Policlinico Casilino, Roma 2 Opedale San Raffaele, Milano

Optimization of stent deployment during percutaneous coronary intervention (PCI) is a key element to obtain most favorable immediate and long-term results. Basic principle of stent-based PCI The bigger = The better

Bigger stent expansion = better outcome Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;15;91:1676–88. Colombo A, et al. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation 1995;15;91:1676–88. Conclusions : the Palmaz-Schatz stent can be safely inserted in coronary arteries without subsequent anticoagulation provided that stent expansion is adequate. High-pressure final balloon dilatations (14.9 ± 3.0 atm) and confirmation of adequate stent expansion by intravascular ultrasound provide assurance that anticoagulation therapy can be safely omitted. This technique significantly reduces hospital time and vascular complications and has a low stent thrombosis rate (1.6%).

Bigger DES expansion = better outcome? After the introduction of drug-eluting stents (DES), the importance of optimal stent deployment was initially underestimated, leading to less use of high pressure deployment and/or balloon post-dilation.

Conclusion: SES had a considerably lower optimal MSA threshold compared to BMS Bigger DES expansion = better outcome? Cypher Bx Velocity Sonoda S, et al. J Am Coll Cardiol 2004

Hoffmann R,et al. Catheter Cardiovasc Interv 2005 A comparison study between SIRIUS-US (pre- and post- dilation) and E-SIRIUS (direct stenting and non mandatory post-dilation) IVUS results showed that, although the less aggressive stent implantation in E-SIRIUS resulted in a relatively lower stent expansion, no detrimental effects were observed in major adverse cardiac events. Bigger DES expansion = better outcome?

= edge restenosis Sakurai R, et al. Am J Cardiol 2005

Bigger DES expansion = better outcome? Sakurai R, et al. Am J Cardiol 2005 = edge restenosis

Magnitude of suboptimal stent expansion Because stent under-expansion is poorly recognized by angiography, the real incidence of suboptimal stent deployment is likely to be underestimated.

Before post-dilationAfter post-dilation

Determinants of Suboptimal Stent Deployment 1. Stent undersizing (balloon to artery ratio <1) : (certainly the first and the most important) (certainly the first and the most important) severe and diffuse target vessel; small vessel; acute coronary syndrome; severe stenosis; direct stenting. In case of undersizing of the stent delivery balloon, high- pressure deployment can compensate for the balloon undersizing only in part!

Determinants of Suboptimal Stent Deployment 2. : 2. Balloon compliance and pressure deployment : (the most unknown) (the most unknown) Stent manufacturers provide a compliance chart relating balloon deployment pressure and the stent diameter based on in vitro measurement (in air or in water). Several IVUS studies found that the real MSD after stent deployment was 20-26% less than the unconstrained stent size displayed in the compliance chart on the stent box. These differences were independent of stent manufacturer, length, diameter, and deployment pressure and related to the inherent resistance of dilating stent within an atherosclerotic artery.

Intravascular ultrasound assessment of drug-eluting stent expansion De Ribamar Costa Am Heart J 2007 According to the compliance chart, DES achieved 75% ± 10% of predicted MSD66% ± 17% of predicted MSA 24% of SES and 28% of PES did not achieve a final MSA of 5 mm2

Intravascular ultrasound assessment of drug-eluting stent expansion De Ribamar Costa Am Heart J no significant difference in stent expansion between DES and their BMS equivalent

Determinants of Suboptimal Stent Deployment 3. Plaque and vessel compliance : (the most unpredictable) (the most unpredictable) In IVUS studies, arterial expansion seemed to be the primary mechanism of lumen enlargement after stenting, accounting for approximately 70% of luminal gain, whereas the relative contribution of plaque reduction ranged between 6% and 34%. Causes of impaired compliance: vessel fibrosis calcium high plaque burden previous stent implantation Boschat J et al. Int J Cardiovasc Imaging 2002

Intravascular ultrasound assessment of drug-eluting stent expansion Stent expansion cannot be predicted from pre-intervention IVUS lesion assessment De Ribamar Costa Am Heart J. 2007

Determinants of Suboptimal Stent Deployment 3. Plaque and vessel compliance : high plaque burden Yoon Sc, et al. Catheter Cardiovasc Interv IVUS success rate % 67.6% 45.7%

Determinants of Suboptimal Stent Deployment 3. Plaque and vessel compliance : Calcium Calcium Stent symmetry index P = Albrecht D, et al. Cathet Cardiovasc Diagn 1996 minimal/maximal stent diameter

Determinants of Suboptimal Stent Deployment 3. Plaque and vessel compliance : Calcium Calcium Vavuranakis M, et al. Cathet Cardiovasc Intervent 2001 Baseline Stent 16 atm Stent at 20 atm

Determinants of Suboptimal Stent Deployment 4. Lesion characteristics : (certainly the most predictable) (certainly the most predictable) Specific lesion subsets are associated with a lower success rate and required more care and tools to obtain an optimal stent deployment Specific lesion subsets are associated with a lower success rate and required more care and tools to obtain an optimal stent deployment: bifurcation lesion (side branch ostium, kissing balloon); ostial lesion (fibrosis) long lesion (proximal-distal vessel size mismatch, overlap) small vessel (vessel overstretch) in stent restenosis

For these causes, the use of a noncompliant balloon post-dilation represents a good compromise to achieve good stent expansion and symmetry without increasing risk of dissection or rupture of the vessel. Determinants of Suboptimal Stent Deployment 1. Stent undersizing (balloon to artery ratio <1) 2. Balloon compliance and pressure deployment 3. Plaque and vessel compliance 4. Lesion characteristics

High pressure stent deployment vs. non-compliant balloon postdilation High pressure stent deployment vs. non-compliant balloon postdilation Bermejo J, et al. Circulation 1998 Despite high-pressure deployment, lumen dimensions after stenting are only 57% of maximal achievable. Inadequate balloon expansion and elastic recoil are responsible for residual lumen stenosis

High pressure stent deployment vs. non-compliant balloon postdilation High pressure stent deployment vs. non-compliant balloon postdilation Jose de Ribamar Costa et al, American Heart Journal 2007 Post-dilation with the stent balloon is not sufficient

Mean Minimum Stent CSA According to Post-dilation Balloon Size Mean Minimum Stent CSA According to Post-dilation Balloon Size Balloon Size (mm) IVUS Derived Final stent CSA (mm 2 )

Seung-Ho Hur. Am J Cardiol 2001 Efficacy of Post-deployment Balloon Dilatation for Bare Metal Stents as Assessed by Intravascular Ultrasound Minimal stent area P <0.001 Stent volume index P <0.001

Efficacy of Post-deployment Balloon Dilation for Bare Metal Stents as Assessed by Intravascular Ultrasound

Seung-Ho Hur. Am J Cardiol 2001 Stent CSA / reference CSA After stent deployment (stent/vessel ratio 1.1) After non compliant post dilation (balloon vessel/ratio 1.1) Efficacy of Post-deployment Balloon Dilation for Bare Metal Stents as Assessed by Intravascular Ultrasound

POST-IT Trial protocol Brodie BR, et al. Catheter Cardiovasc Interv 2003 Lesion predilation YesNo Stenting with delivery balloon (ballon/vessel ratio 1.1) IVUS assessment IVUS criteria for optimum stent deployment met? Post-dilate with NC balloon (ballon/vessel ratio 1.1) IVUS assessment IVUS criteria for optimum stent deployment met?Yes Procedure end

High pressure stent deployment vs. non-compliant balloon postdilation High pressure stent deployment vs. non-compliant balloon postdilation Brodie BR, et al. Catheter Cardiovasc Interv % 42% 6,6% 7,8% P < 0.01 MUSIC criteria satisfied MSA

High pressure stent deployment vs. non-compliant balloon postdilation High pressure stent deployment vs. non-compliant balloon postdilation Brodie BR, et al. Catheter Cardiovasc Interv 2003 MSD 2.2MSD x 18 mm stent delivery balloon at 14 atm 3.0 x 15 mm non-compliant balloon at 14 atm

Risk of “dog bone”/edge effect with an SC balloon at high pressure NC balloon at high pressure Semi Compliant Non Compliant Semi-compliant vs. non-compliant balloon

Non compliant balloon Quantum 4.0 x 15 mm Standard stent delivery balloon 4.0 x 16 mm

Pre-Optimization Post-Optimization High pressure stent deployment vs. non-compliant balloon postdilation High pressure stent deployment vs. non-compliant balloon postdilation Avoid the Donkey effect!

Benefits of a NC balloon post-dilation after DES implantation Benefits of a NC balloon post-dilation after DES implantation In-stent restenosis: complete stent struts apposition; higher luminal MSA (<5 mm 2 threshold); stent symmetry (homogeneous drug release) Observational data suggest that stent under-expansion might be one of the most important causes of DES failure, advocating that, once neo-intimal hyperplasia is suppressed, the optimum stent deployment is still fundamental

Under deployment is a cause for In-Stent Restenosis  20% Castagna MT, et al. American Heart Journal 2001 Results from a retrospective study of patients

Benefits of a NC balloon post-dilation after DES implantation Benefits of a NC balloon post-dilation after DES implantation Stent thrombosis (0.4%-0.6% of RCT up to of registry) complete stent struts apposition; stent underexpansion (shear stress); reduced edge dissection shorter dual antiplatelet therapy In this view, the less care used by operators to obtain an optimal stent deployment and a lower use of post- dilation might represent a possible explanation of the higher rates of stent thrombosis observed with DES

Under deployment is the main cause for subacute thrombosis 78% Cheneau E, et al. Circulation Results from 7484 consecutive patients without acute MI

Stent underexpansion is an independent predictor of subacute stent thrombosis 4.3 +/ /- 1.9 Minimum stent CSA Stent expansion Stent thrombosis group (SES) Matched control group (SES) vs / / Fujii, K, et al. Journal of the American College of Cardiology 2005 p < 0.001

How to select and post-dilate with an non-compliant balloon Angiograph y-guided strategy Select a non- compliant balloon Shorter than the stent 0.50 mm larger than the stent delivery balloon Deploy at gradual high pressures i.e. >24 atm

ConclusionsConclusions Which is the role of post-dilation after DES implantation? In clinical practice, a considerable number of patients might benefit from repeat inflations with non-compliant balloons at higher pressures and/or with larger diameter size. Data from the literature suggest that achieving adequate stent expansion during PCI is important to reduce restenosis and the need for TVR, but it might also minimize the risk of stent thrombosis in the DES era.

N None of the baseline clinical or angiographic variables seemed able to predict the final MSA or MSD after stenting. Similarly, neither quantitative IVUS lesion measurements nor qualitative IVUS assessment of plaque morphology could predict stent expansion. These observations would suggest that the impact of plaque and vessel compliance on the final stent expansion can be limited by an appropriate use of post-dilation. ConclusionsConclusions Which is the role of post-dilation after DES implantation?

Although there are not enough randomized data to support its use, it seems wise to perform post-dilation with non- compliant balloons at high pressures in the majority of patients undergoing both BMS and DES implantation. Although there are not enough randomized data to support its use, it seems wise to perform post-dilation with non- compliant balloons at high pressures in the majority of patients undergoing both BMS and DES implantation. Particularly in IVUS-guided procedures, the recommended strategy to achieve an optimal stent deployment should be to select a noncompliant balloon whose size matches the media-to-media IVUS measurement. Particularly in IVUS-guided procedures, the recommended strategy to achieve an optimal stent deployment should be to select a noncompliant balloon whose size matches the media-to-media IVUS measurement. ConclusionsConclusions Which is the role of post-dilation after DES implantation?

Reference: Romagnoli et al. JACC intv. 2008;1:45-56 Romagnoli et al. JACC intv. 2008;1:45-56Romagnoli et al. JACC intv. 2008;1:45-56 Slides available at: www. metcardio.org www. metcardio.orgwww. metcardio.org Which is the role of post-dilation after DES implantation? Enrico Romagnoli 1,2 M.D., Ph.D.